SCHOTT Pharma AG & Co KgaA
XETRA:1SXP

Watchlist Manager
SCHOTT Pharma AG & Co KgaA Logo
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Watchlist
Price: 24.76 EUR 1.81% Market Closed
Market Cap: 3.7B EUR
Have any thoughts about
SCHOTT Pharma AG & Co KgaA?
Write Note

SCHOTT Pharma AG & Co KgaA
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SCHOTT Pharma AG & Co KgaA
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Cost of Revenue
-€582.1m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
Evotec SE
XETRA:EVT
Cost of Revenue
-€670.6m
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
-28%
Gerresheimer AG
XETRA:GXI
Cost of Revenue
-€1.4B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
No Stocks Found

SCHOTT Pharma AG & Co KgaA
Glance View

Market Cap
3.7B EUR
Industry
Life Sciences Tools & Services

SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe. SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.

1SXP Intrinsic Value
32.11 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is SCHOTT Pharma AG & Co KgaA's Cost of Revenue?
Cost of Revenue
-582.1m EUR

Based on the financial report for Sep 30, 2023, SCHOTT Pharma AG & Co KgaA's Cost of Revenue amounts to -582.1m EUR.

What is SCHOTT Pharma AG & Co KgaA's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-14%

Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for SCHOTT Pharma AG & Co KgaA have been -14% over the past three years .

Back to Top